Terkko Navigator / Lancet Oncology

Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis

Theranos: the proof that public regulation matters

Promising outlook with sugemalimab in non-small-cell lung cancer

Targeting HER2 for localised oesophageal cancer

Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, pha

Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

Overcoming immunotherapy resistance in NSCLC

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-

Is non-invasive Cytosponge the holy grail for Barrett's neoplasia?

Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

The tumours and the three bumps

Clinical advances in PET–MRI for breast cancer

European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer

WHO and St Jude Children's Research Hospital announce childhood cancer medicines initiative

San Antonio Breast Cancer Symposium 2021

63rd ASH Annual Meeting and Exposition

Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial

Postoperative radiotherapy in resected N2 non-small-cell lung cancer: Lung ART

KRASG12C inhibition in colorectal cancer

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial

Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study

Study of the Veterans Affairs Health Care System highlights the impact of COVID-19 on cancer diagnoses in the USA

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study

Rs708113 in WNT3A-WNT9A and hepatocellular carcinoma risk

Risk-based lung cancer screening eligibility criteria: towards implementation

All eyes on the EuroNet-PHL-C1 trial for paediatric classical Hodgkin lymphoma

Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded,

HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study

CAR T-cell therapy for indolent lymphoma: a new treatment paradigm?

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Burden of cancer in adolescents and young adults

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study

The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019

COVID-19 pandemic to lead to thousands of additional UK lung cancer deaths

Diplopia, proptosis, and the pancreas

Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromes

Immunotherapy for cancer treatment during pregnancy

Financial toxicity in cancer care in India: a systematic review

Build Back Better Act could affect US community-based oncology practices

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

Targeting BRAF-mutant glioma: reflections on the ROAR trial

New coalition to harmonise USA–China cancer research and care